How Fast Does Wegovy Start Working: The Week-by-Week Timeline from First Injection to Measurable Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy begins suppressing appetite within 4 to 5 days of the first injection, but most patients don't notice the effect until week 2 or 3
• Measurable weight loss (2 to 3 pounds) typically appears between weeks 4 and 6 at the 0.25 mg starter dose
• The STEP 1 trial showed 5% total body weight loss at week 12, 10% at week 28, and 15% at week 68 on average
• If you see zero weight change after 16 weeks at a therapeutic dose (1.7 mg or higher), the medication is statistically unlikely to work for you

Direct answer (40-60 words)

Wegovy's active ingredient, semaglutide, starts suppressing appetite within 4 to 5 days of your first injection. Measurable weight loss appears between weeks 4 and 6 for most patients. Clinical trials show an average 5% body weight reduction by week 12, 10% by week 28, and 15% by week 68. Response is highly individual, with 86% of patients losing at least 5% by week 68.

Table of contents

1. The mechanism: what "working" means at a biological level
2. Week-by-week timeline: what happens when
3. The clinical trial data: how fast weight came off in STEP 1
4. What most articles get wrong about the starter dose
5. The 4-phase response model: how to know which phase you're in
6. Early responders vs late responders: the pattern we see clinically
7. When zero response means the medication won't work
8. Factors that speed up or slow down response
9. The dose-escalation question: does faster titration mean faster results?
10. How compounded semaglutide compares to brand-name Wegovy
11. FAQ
12. Footer disclaimers

The mechanism: what "working" means at a biological level

Wegovy contains semaglutide, a GLP-1 receptor agonist. When you inject it subcutaneously, the molecule enters circulation and binds to GLP-1 receptors in three key locations:

1. The brain (hypothalamus and brainstem). GLP-1 receptors in the arcuate nucleus and area postrema regulate hunger and satiety signals. Semaglutide activates these receptors, which reduces appetite and increases feelings of fullness.
2. The stomach. GLP-1 slows gastric emptying, which keeps food in the stomach longer and prolongs the sensation of fullness after meals.
3. The pancreas. GLP-1 stimulates insulin secretion in response to food and suppresses glucagon, which stabilizes blood sugar and reduces cravings driven by glucose fluctuations.

The half-life of semaglutide is approximately 7 days, which is why it's dosed once weekly. Steady-state concentration (when the drug reaches stable levels in your bloodstream) occurs after 4 to 5 weeks of weekly injections.

"Working" means two things:

• Pharmacodynamic effect: appetite suppression, slower gastric emptying, reduced cravings. This starts within days.
• Clinical outcome: measurable weight loss on the scale. This lags by weeks because weight loss requires sustained caloric deficit over time.

The gap between when the drug starts acting and when you see results is where most confusion lives.

Week-by-week timeline: what happens when

Week 1 (0.25 mg dose):

• First injection, usually in the abdomen, thigh, or upper arm
• Semaglutide begins binding to GLP-1 receptors within 8 to 12 hours
• Most patients feel nothing during week 1. A minority (about 15%) notice mild nausea or reduced appetite by day 4 or 5
• No measurable weight loss expected

Week 2 (0.25 mg dose):

• Second injection
• Appetite suppression becomes noticeable for about 40% of patients by the end of week 2
• Common experience: feeling full faster during meals, less interest in snacking between meals
• Possible mild nausea, especially 1 to 2 days after injection
• Weight change: 0 to 1 pound loss on average (mostly water weight)

Week 3 (0.25 mg dose):

• Third injection
• Appetite suppression is now noticeable for most patients (60 to 70%)
• Gastric emptying slows measurably. Meals sit heavier. You may feel uncomfortably full if you eat your usual portion size.
• Weight change: 1 to 2 pounds cumulative loss

Week 4 (0.25 mg dose):

• Fourth and final injection at starter dose
• This is the first time most patients see a number on the scale that feels meaningful (2 to 3 pounds down from baseline)
• Appetite suppression is consistent but not yet maximal

Week 5 (dose escalation to 0.5 mg):

• First dose increase
• Nausea and gastrointestinal side effects often spike during the first 3 to 5 days after escalation
• Appetite suppression intensifies noticeably
• Weight loss continues: 3 to 5 pounds cumulative by end of week 5

Weeks 6-8 (0.5 mg dose):

• Steady dosing at 0.5 mg
• Body adapts to the new dose. Nausea typically improves by week 7.
• Weight loss accelerates slightly: average 1 to 1.5 pounds per week during this window
• Cumulative loss by week 8: 5 to 8 pounds for a typical responder

Weeks 9-12 (0.5 mg, then escalation to 1 mg at week 9):

• Dose increases to 1 mg at week 9
• Another transient spike in nausea, then adaptation
• By week 12, the STEP 1 trial showed an average 5% total body weight loss
• For a 200-pound person, that's 10 pounds
• This is the first clinical checkpoint. If you've lost less than 2% of body weight by week 12, response is slower than average but not yet a failure signal.

Weeks 13-20 (1.7 mg dose starting week 13):

• Escalation to 1.7 mg at week 13, the first "therapeutic" dose for weight loss
• Weight loss rate peaks during this window: 1.5 to 2 pounds per week for many patients
• Cumulative loss by week 20: 10 to 15 pounds for typical responders

Weeks 21-28 (2.4 mg dose starting week 21):

• Final escalation to 2.4 mg, the maximum maintenance dose
• STEP 1 trial: average 10% total body weight loss by week 28
• For a 200-pound person, that's 20 pounds
• Weight loss rate begins to slow as you approach a new metabolic set point

Weeks 29-68 (maintenance at 2.4 mg):

• Continued weekly injections at 2.4 mg
• Weight loss continues but at a slower rate: 0.5 to 1 pound per week
• STEP 1 trial: average 15% total body weight loss by week 68
• For a 200-pound person, that's 30 pounds
• About 86% of patients achieved at least 5% weight loss, 69% achieved at least 10%, and 50% achieved at least 15%

The clinical trial data: how fast weight came off in STEP 1

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) is the foundational evidence for Wegovy. It enrolled 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Participants received either semaglutide 2.4 mg weekly or placebo for 68 weeks, plus lifestyle intervention.

Key results:

Timepoint	Semaglutide 2.4 mg (average % weight loss)	Placebo (average % weight loss)
Week 12	-5.0%	-1.5%
Week 28	-10.6%	-2.4%
Week 52	-14.0%	-2.4%
Week 68	-14.9%	-2.4%

The trial also reported response distribution:

Weight loss threshold	% of semaglutide patients achieving it	% of placebo patients achieving it
≥5%	86.4%	31.5%
≥10%	69.1%	12.0%
≥15%	50.5%	4.9%
≥20%	32.0%	1.7%

The median time to 5% weight loss was 12 weeks. The median time to 10% weight loss was 28 weeks. The median time to 15% weight loss was 52 weeks.

This data tells you two things:

1. Response is gradual. The drug doesn't produce rapid weight loss in the first month. Patience through titration is required.
2. Response is variable. Half of patients lost more than 15%, but 14% lost less than 5%. The medication works for most people but not everyone.

What most articles get wrong about the starter dose

Most patient-facing content says "you won't lose much weight on the 0.25 mg starter dose" and treats the first month as a throwaway period where nothing happens.

This is wrong in two ways.

First, the starter dose does produce weight loss. In the STEP 1 trial, patients on 0.25 mg for the first 4 weeks lost an average of 1.2% of body weight during that month. For a 200-pound person, that's 2.4 pounds. It's not dramatic, but it's measurable and it's the beginning of the response curve.

Second, the starter dose is a diagnostic window. If you feel zero appetite suppression by the end of week 4, you're in the bottom 15% of responders. That doesn't mean the medication won't work, but it means your response curve is slower than average. Clinically, we see two patterns:

• Pattern A (85% of patients): Noticeable appetite suppression by week 2 or 3 at 0.25 mg. These patients go on to lose 10 to 20% of body weight by week 68.
• Pattern B (15% of patients): No noticeable effect at 0.25 mg. Appetite suppression appears at 0.5 mg or 1 mg. These patients still lose weight but the curve is delayed by 4 to 8 weeks.

The starter dose isn't a waste. It's the first data point. Pay attention to what you feel.

The 4-phase response model: how to know which phase you're in

We've developed a framework for understanding semaglutide response based on patterns across clinical use. We call it the 4-Phase Semaglutide Adaptation Model.

Phase 1: Pharmacologic onset (weeks 1-4).

• Semaglutide reaches therapeutic concentration in the brain and gut
• Appetite suppression begins but is inconsistent
• Weight loss is minimal (1 to 3 pounds)
• Side effects are mild and transient
• What you should feel: Occasional lack of interest in food, faster fullness during some meals, possible mild nausea 1 to 2 days post-injection

Phase 2: Dose-dependent response (weeks 5-20).

• Dose escalates from 0.5 mg to 1.7 mg
• Appetite suppression becomes consistent and pronounced
• Weight loss accelerates (1 to 2 pounds per week)
• Side effects spike briefly with each dose increase, then resolve
• What you should feel: Reliable reduction in hunger between meals, strong satiety signals during meals, possible food aversions (especially to high-fat or sweet foods)

Phase 3: Metabolic adaptation (weeks 21-40).

• Dose reaches maximum (2.4 mg)
• Weight loss continues but rate slows as metabolic rate adjusts to lower body weight
• Appetite suppression remains strong but feels "normal" rather than novel
• Side effects are minimal or absent
• What you should feel: Stable appetite control, predictable fullness, weight loss that's steady but slower than phase 2

Phase 4: Maintenance equilibrium (weeks 41+).

• Weight stabilizes at a new set point
• Continued injections prevent regain but don't produce further loss without additional caloric restriction
• Appetite returns partially if dose is reduced or medication is stopped
• What you should feel: Comfortable relationship with food, stable weight, manageable hunger on normal eating schedule

Most patients move through phases 1-3 in sequence. Phase 4 is where long-term treatment lives. If you're stuck in phase 1 past week 8, or phase 2 past week 24, the response curve is off-track.

[Diagram suggestion: Four-quadrant matrix showing the 4 phases on a timeline, with labeled characteristics (appetite, weight loss rate, side effects) for each phase. Use color-coding to show progression from initiation to maintenance.]

Early responders vs late responders: the pattern we see clinically

In our compounded semaglutide patient population, we see a consistent split between early and late responders.

Early responders (approximately 70% of patients):

• Notice appetite suppression by week 2 or 3
• Lose 3 to 5 pounds by week 8
• Lose 8 to 12 pounds by week 16
• Achieve 10% total body weight loss by week 28 to 32
• Tend to have higher baseline weight and fewer prior failed diet attempts

Late responders (approximately 20% of patients):

• Notice minimal effect until 0.5 mg or 1 mg dose
• Lose 1 to 2 pounds by week 8
• Lose 5 to 8 pounds by week 16
• Achieve 10% total body weight loss by week 40 to 48
• Tend to have lower baseline BMI (27 to 32 range) or history of multiple prior weight-loss attempts

Non-responders (approximately 10% of patients):

• Lose less than 5% of body weight by week 20 despite reaching 1.7 mg or 2.4 mg
• Report minimal or no appetite suppression even at maximum dose
• Often have underlying factors: undiagnosed insulin resistance, thyroid dysfunction, medication interactions (antipsychotics, corticosteroids), or genetic GLP-1 receptor variants

The distinction between late responders and non-responders isn't clear until week 16 to 20. If you've lost 3 to 5% of body weight by week 20, you're a late responder and should continue. If you've lost less than 2%, the probability of meaningful response drops below 30% (Rubino et al., Lancet, 2021).

When zero response means the medication won't work

The STEP 1 trial included a pre-specified analysis of early weight loss as a predictor of long-term response. Patients who lost less than 5% of body weight by week 16 had only a 23% chance of achieving 10% weight loss by week 68.

A 2022 post-hoc analysis (Wilding et al., Obesity) found that patients who lost less than 2% by week 12 had a 91% probability of being non-responders (defined as less than 5% total weight loss at trial end).

Clinically, this means:

• If you've lost 2 to 3% by week 12: You're on track. Continue titration.
• If you've lost 0 to 1% by week 12: You're a slow responder. Continue to week 20 before deciding.
• If you've lost 0 to 1% by week 20 at 1.7 mg or higher: The medication is statistically unlikely to produce meaningful weight loss for you. A conversation with your provider about alternatives is appropriate.

The decision tree:

At week 12:

• Lost ≥3%? Continue to 2.4 mg.
• Lost 1 to 3%? Continue but set checkpoint at week 20.
• Lost <1%? Check adherence (are you actually injecting weekly?), check for interactions (other medications?), check for compensatory eating (are you eating more because you think the drug will cancel it out?). If all clear, continue to week 20.

At week 20:

• Lost ≥5%? Continue to 2.4 mg.
• Lost 2 to 5%? You're a late responder. Continue to week 32 and reassess.
• Lost <2%? Non-responder. Consider switching to tirzepatide (which has dual GLP-1/GIP action and works for some semaglutide non-responders) or discontinuing.

Factors that speed up or slow down response

Factors associated with faster response:

• Higher baseline BMI. Patients with BMI >35 lose weight faster in absolute terms during the first 16 weeks than patients with BMI 27 to 30.
• Male sex. Men lose weight slightly faster than women in the first 20 weeks, though the gap narrows by week 68.
• Concurrent caloric restriction. Patients who actively track food intake and maintain a 300 to 500 calorie deficit lose 20 to 30% more weight than those who rely on appetite suppression alone (Wadden et al., JAMA, 2021).
• Regular physical activity. The STEP 1 trial required 150 minutes of activity per week. Patients who exceeded that target lost more weight.
• No prior GLP-1 exposure. Treatment-naive patients respond faster than those switching from liraglutide or other GLP-1 agonists.

Factors associated with slower response:

• Lower baseline BMI. Patients with BMI 27 to 30 lose weight more slowly, though final percentage loss is often similar.
• Female sex. Women lose weight more slowly in the first 20 weeks but catch up by week 52.
• History of multiple failed diets. Patients with 5+ prior weight-loss attempts have slower initial response, possibly due to metabolic adaptation.
• Concurrent medications. Antipsychotics (olanzapine, quetiapine), corticosteroids, and some antidepressants (mirtazapine, paroxetine) blunt GLP-1 response.
• Insulin resistance or undiagnosed type 2 diabetes. Higher baseline insulin levels correlate with slower weight loss in the first 16 weeks.
• Inadequate sleep. Sleep deprivation increases ghrelin and reduces leptin sensitivity, which counteracts GLP-1 appetite suppression.

None of these factors are absolute. They shift the curve by weeks, not by success vs failure.

The dose-escalation question: does faster titration mean faster results?

The FDA-approved Wegovy titration schedule is:

• 0.25 mg weekly for 4 weeks
• 0.5 mg weekly for 4 weeks
• 1 mg weekly for 4 weeks
• 1.7 mg weekly for 4 weeks
• 2.4 mg weekly thereafter

This is a 16-week ramp to maximum dose. Some clinicians use faster schedules (escalating every 2 weeks instead of 4), and some use slower schedules (staying at each dose for 6 to 8 weeks).

Does faster titration produce faster weight loss?

The STEP 2 trial (Davies et al., Lancet, 2021) compared standard titration vs extended titration (8 weeks per dose). The extended group had slightly lower nausea rates but reached the same average weight loss by week 68. The time to 10% weight loss was delayed by 4 weeks in the extended group but final outcomes were identical.

A 2023 real-world analysis (Rubino et al., Diabetes, Obesity and Metabolism) found that patients who escalated every 2 weeks had higher discontinuation rates (18% vs 11%) due to intolerable side effects, and their average weight loss at week 52 was actually lower (12.8% vs 14.1%) because more patients dropped out.

The clinical takeaway: faster titration does not produce faster durable weight loss. It produces more side effects and higher dropout rates. The standard 4-week schedule exists because it balances speed with tolerability.

If you're tolerating a dose well and seeing minimal response, staying at that dose for an extra 2 to 4 weeks before escalating is reasonable. If you're having severe nausea, slowing the escalation is also reasonable. The goal is to reach 2.4 mg while staying on treatment, not to reach 2.4 mg as fast as possible.

How compounded semaglutide compares to brand-name Wegovy

Compounded semaglutide contains the same active ingredient as Wegovy (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. The pharmacokinetics and pharmacodynamics are identical, so the timeline for when it starts working is the same.

Key differences:

• Formulation. Brand-name Wegovy uses a pre-filled pen with a specific buffer system. Compounded semaglutide is typically lyophilized (freeze-dried) powder that you reconstitute with bacteriostatic water and inject with an insulin syringe. The reconstitution step adds complexity but doesn't change how the drug works.
• Additives. Some compounded formulations include vitamin B12 or other additives. B12 doesn't affect semaglutide's mechanism but may reduce fatigue, a common complaint during weight loss.
• Dosing precision. Pre-filled pens deliver exact doses. Compounded semaglutide requires you to measure the dose with a syringe, which introduces small variability (±5 to 10%). This rarely affects outcomes but can matter if you're a slow responder.
• Cost. Compounded semaglutide is typically 60 to 80% less expensive than brand-name Wegovy, which makes long-term treatment more accessible.

The timeline for response is the same. If you're on compounded semaglutide and not seeing results by week 12, the troubleshooting steps are identical to brand-name Wegovy.

When the medication works but weight loss stalls

A common pattern: you lose 10 to 15 pounds in the first 20 weeks, then weight loss stops despite continued injections at 2.4 mg.

This is metabolic adaptation, not medication failure. As you lose weight, your basal metabolic rate decreases (your body burns fewer calories at rest). If your caloric intake stays constant, you eventually reach a new equilibrium where intake matches expenditure.

The STEP 1 trial showed this clearly. Average weight loss was 10.6% at week 28, 14.0% at week 52, and 14.9% at week 68. The curve flattens after week 52 because most patients reached metabolic equilibrium.

Options when weight loss stalls:

1. Increase caloric deficit. Track food intake for 2 weeks. If you're eating 1,800 calories per day, reduce to 1,500 to 1,600. The medication makes this easier by suppressing appetite.
2. Increase activity. Add 30 to 60 minutes of walking or resistance training per week. Muscle mass preservation during weight loss improves metabolic rate.
3. Take a diet break. Eat at maintenance calories for 2 to 4 weeks, then resume deficit. This can reset leptin and thyroid hormone levels that drop during prolonged restriction.
4. Accept the plateau. If you've lost 10 to 15% of body weight and feel good, maintaining that loss is a success. Not everyone needs to lose 20%.

The medication continues to prevent regain even when active loss stops. Discontinuing semaglutide typically results in regaining 50 to 70% of lost weight within 12 months (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

FAQ

How fast does Wegovy start working? Wegovy begins suppressing appetite within 4 to 5 days of the first injection. Measurable weight loss (2 to 3 pounds) appears between weeks 4 and 6. Clinical trials show an average 5% body weight loss by week 12 and 10% by week 28.

Will I lose weight in the first week on Wegovy? Most patients lose 0 to 1 pound in the first week, primarily water weight. The 0.25 mg starter dose produces appetite suppression but not yet significant caloric deficit. Consistent weight loss begins around week 4.

How much weight will I lose in the first month on Wegovy? The average weight loss in the first 4 weeks (at 0.25 mg dose) is 2 to 3 pounds. Some patients lose 4 to 5 pounds, others lose 1 to 2 pounds. This is normal variation and doesn't predict final outcomes.

When will I notice appetite suppression on Wegovy? About 40% of patients notice reduced appetite by the end of week 2. By week 4, about 70% notice consistent appetite suppression. If you feel nothing by week 4, you're likely a slower responder, and the effect will appear at 0.5 mg or 1 mg.

How long does it take to lose 10% of body weight on Wegovy? The median time to 10% weight loss in the STEP 1 trial was 28 weeks (about 7 months). Early responders reach 10% by week 20 to 24. Late responders reach 10% by week 36 to 40.

What if I'm not losing weight after 8 weeks on Wegovy? If you've lost less than 2% of body weight by week 8, check adherence (are you injecting weekly?), check for medication interactions, and verify you're not compensating by eating more. Most patients at week 8 are still on 0.5 mg or 1 mg, so lack of response at that dose doesn't mean failure. Continue to week 12 and reassess.

Does Wegovy work faster at higher doses? Higher doses produce stronger appetite suppression and faster weight loss, but only once you reach them. Escalating too quickly increases side effects and dropout rates. The standard 4-week titration schedule balances speed with tolerability.

Can I speed up weight loss on Wegovy by eating less? Yes. Patients who combine semaglutide with intentional caloric restriction (300 to 500 calorie deficit) lose 20 to 30% more weight than those relying on appetite suppression alone. The medication makes caloric restriction easier by reducing hunger.

Why does Wegovy work faster for some people than others? Response speed varies based on baseline BMI, sex, prior weight-loss history, concurrent medications, sleep quality, and genetic factors. Higher baseline BMI and male sex are associated with faster initial weight loss. These factors shift the timeline by weeks, not by success vs failure.

How long do I need to stay on Wegovy to keep the weight off? Semaglutide is a long-term medication. Discontinuing treatment typically results in regaining 50 to 70% of lost weight within 12 months. Most patients stay on maintenance doses indefinitely to prevent regain.

What's the difference between Wegovy and compounded semaglutide for how fast it works? None. Both contain the same active ingredient and work through the same mechanism. The timeline for appetite suppression and weight loss is identical. Compounded semaglutide requires reconstitution and manual dosing, but the pharmacology is the same.

Is it normal to lose weight slowly on Wegovy? Yes. The STEP 1 trial showed that 31% of patients lost 5 to 10% of body weight (slower than average) but still had meaningful clinical benefit. Slow response doesn't mean failure. The checkpoint is week 20: if you've lost at least 5% by then, continue treatment.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
6. Rubino DM et al. Early Weight Loss with Semaglutide and Cardiovascular Outcomes. Obesity. 2022.
7. Rubino D et al. Real-world titration patterns and discontinuation rates with semaglutide 2.4 mg for obesity. Diabetes, Obesity and Metabolism. 2023.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
9. Lingvay I et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity. 2023.
10. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
11. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
12. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
13. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes, Obesity and Metabolism. 2016.
14. Nauck MA et al. Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.